Saturday, October 31, 2026

Fed's Daly Signals Pause in Rate Hikes as Tariff Impact Stays Contained, Markets Rally 2%+

Major U.S. equity indices surged November 11, 2025, with the S&P 500 gaining over 2% after Fed official Mary Daly indicated tariff effects remain limited to goods prices while wage growth moderates. The rally gained momentum as White House backing for a bipartisan shutdown deal removed political uncertainty. Technology and AI semiconductor stocks led gains.

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Fed's Daly Signals Pause in Rate Hikes as Tariff Impact Stays Contained, Markets Rally 2%+
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

U.S. equity markets posted their strongest single-day advance in months on November 11, 2025, with major indices climbing more than 2% following Federal Reserve signals that aggressive rate policy shifts remain unlikely.

Mary Daly, San Francisco Fed President, told markets that tariff impacts "have largely been confined to goods, with little spillover into services inflation or inflation expectations, which remain relatively well-anchored around our 2% target." The statement marked a shift from earlier Fed concerns about broad-based price pressures from trade policy.

Daly cited moderating wage growth and labor market softening as reasons to avoid extended high rates. "We don't want to make the mistake of holding on too long to high interest rates only to find out we've injured the economy," she said, signaling the Fed's growing comfort with current policy stance.

The monetary policy clarity coincided with reduced political risk. White House support for a bipartisan deal to avoid a government shutdown removed a key uncertainty that had weighed on investor sentiment in prior sessions. The dual catalysts—stable Fed policy and resolved fiscal drama—triggered broad risk-on positioning across asset classes.

Technology stocks led the advance, with AI semiconductor companies posting outsized gains. The sector's strength reflected investor confidence that growth stocks can extend their rally within a stabilizing macro environment where the Fed neither tightens aggressively nor signals imminent recession concerns.

The rally's breadth suggested institutional investors are repositioning for a scenario where inflation moderates without requiring deep rate cuts or triggering hard landing dynamics. Daly's comments on anchored inflation expectations gave markets permission to price out tail risks that had compressed valuations earlier in the quarter.

Fixed income markets showed muted reaction, with Treasury yields holding steady as investors interpreted Daly's remarks as confirming the current rate path rather than previewing cuts. The lack of bond market volatility supported equity gains by keeping financing costs stable for corporate borrowers.

With tariff effects contained and political gridlock avoided, investor focus now shifts to upcoming economic data releases that will test whether the Fed's relatively sanguine outlook matches labor market and inflation realities in coming months.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleNasdaq· November 10, 2025
    Stocks Finish Sharply Higher on Plans to Reopen the US Government

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com